SCHEMBL13239012

SCHEMBL13239012

c1cc(N2CCCCC2)c2occc2c1

nearest known ligand 0.73

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 0.53
DRD2 P14416 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30992343 1.00 HTR1A (0.53) HTR1ADRD2
SCHEMBL5756036 0.84
SCHEMBL10514753 0.84
SCHEMBL2545146 0.83 HTR3E (0.56) HTR1A
Hydrochloric Acid SCHEMBL10523385 0.81 KDM4E (0.57)
SCHEMBL6583762 0.80
SCHEMBL10512972 0.80 HTR1A (0.52) HTR1ADRD2
Hydrochloric Acid SCHEMBL10515391 0.79 HTR1A (0.51) HTR1ADRD2
SCHEMBL7840531 0.78 HTR1A (0.53) HTR1ADRD2
SCHEMBL10514665 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11998539-B2 Substituted aminoquinolones as DGKalpha inhibitors for immune activation BAYER AKTIENGESELLSCHAFT (DE) 2024-06-04 US disclosed
US-RE41425-E1 used for the treatment of affective disorders or diseases of the central nervous system caused by disturbances in either the dopaminergic or serotinergic systems, such as schizophrenia DUPHAR INTERNATIONAL RESEARCH B.V. (NL) 2010-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11998539-B2 Substituted aminoquinolones as DGKalpha inhibitors for immune activation DGKK, DGKG, DGKA HTR1A 4284/4885DRD2 1404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.